Pharma Industry Animation Marketing

Intra-Cellular Therapies Announces The Successful Completion Of A Phase Ib/II Study Of ITI-007 In Patients With Schizophrenia
Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia...

ANA598 Demonstrates SVR12 In 100% Of First Group Of HCV Patients Randomized To Stop All Treatment At Week 24
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12...

Shionogi Inc. Announces FDA Approval Of CUVPOSAâ„¢ For The Treatment Of Chronic Severe Drooling In Pediatric Patients With Neurologic Conditions
Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSAâ„¢ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSAâ„¢ was designated an Orphan Drug by the FDA...

New Catalytic Process Could Be Used To Create Pharmaceuticals With Less Chemical Waste
Much like two children in the back seat of a car, it can be challenging to get two catalysts to cooperate for the greater good. Now Northwestern University chemists have gotten two catalysts to work together on the same task -- something easily done by nature but a difficult thing to do in the laboratory...

Dispensary Of Hope Welcomes Sanofi-Aventis U.S. As Latest Participant In The Continued Access Program
The Dispensary of Hope is pleased to announce that sanofi-aventis U.S., the U.S. affiliate of sanofi-aventis, a leading global pharmaceutical company, has become the latest pharmaceutical company to participate in the Dispensary's Continued Access Program, which provides uninsured patients with access to medicines that they otherwise couldn't afford...

New Tool For Accessing Bioinformatics Resources
Developed by researchers at the UPM's Facultad de Informática, this tool can discover and automatically classify bioinformatics resources from the scientific literature. Bioinformatics resources have proliferated in the years since the end of the Human Genome Project, obliging researchers to spend a quite a lot of time browsing the web in search of these resources...

New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE IMPACT Study
Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)...

Chimerix's CMX157 Shows Potential To Treat Multi-Drug-Resistant HIV And Improve The Activity And Toxicity Profile Of Tenofovir
Chimerix, Inc...

Topaz Pharmaceuticals Announces Positive Data From Topical Ivermectin Trials Presented At Society Of Pediatric Dermatology
Topaz Pharmaceuticals Inc., a privately held biotechnology company, announced positive results of studies of topical ivermectin cream, which it is developing as a potential treatment of Pediculus humanus capitis (head lice)...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial Of PSI-938 In Patients With Chronic Hepatitis C
Pharmasset, Inc. (Nasdaq: VRUS) announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection...

Abbott's SIMCOR ® ( Niacin Extended-release / Simvastatin ) Receives FDA Approval For New Dosage Strengths
Abbott (NYSE: ABT) received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin the most commonly prescribed dose of simvastatin with either 500 mg or 1,000 mg of niacin extended-release...

Advanced Life Sciences Applies For FDA Fast-Track Designation For Restanza In CABP
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced that the Company has applied to the U.S...

Angiotech Pharmaceuticals And Partner Athersys Announce Positive Results From Phase I Study Of MultiStem(R) In Heart Attack Patients
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack...

NeurogesX Progresses On Coverage For Qutenza®
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced important progress in the implementation of its reimbursement strategy for Qutenza® (capsaicin) 8% patch. Qutenza is currently available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN)...

Encap Drug Delivery Receives Patent Approval For DuoCapTM Capsule System
Encap Drug Delivery, a leading provider of development and manufacturing services to the pharmaceutical industry, has received confirmation that their DuoCapTM, capsule delivery system has been granted patents for US and Europe. DuoCapTM, is a single oral dosage unit that comprises a capsule-in-a-capsule and offers broad therapeutic applications...